Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
Primary Purpose
Asthma
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
budesonide/formoterol
budesonide
formoterol
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, Symbicort, budesonide/formoterol, budesonide, formoterol
Eligibility Criteria
Inclusion Criteria:
- At least 12 years of age
- Diagnosis of asthma
- Baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol
Exclusion Criteria:
- Has required treatment with non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers
- Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
1
2
3
Arm Description
budesonide
formoterol
Outcomes
Primary Outcome Measures
12 hour serial FEV1 measurements and withdrawals due to asthma exacerbation
Secondary Outcome Measures
Lung function, asthma symptoms, use of rescue medication, adverse events and other safety assessments
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00652002
Brief Title
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
Official Title
A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5
Study Type
Interventional
2. Study Status
Record Verification Date
January 2011
Overall Recruitment Status
Completed
Study Start Date
July 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
January 2004 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
AstraZeneca
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to compare Symbicort with budesonide alone and with formoterol alone in the treatment of asthma in adolescents and adults
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, Symbicort, budesonide/formoterol, budesonide, formoterol
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
450 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Active Comparator
Arm Description
budesonide
Arm Title
3
Arm Type
Active Comparator
Arm Description
formoterol
Intervention Type
Drug
Intervention Name(s)
budesonide/formoterol
Other Intervention Name(s)
Symbicort
Intervention Type
Drug
Intervention Name(s)
budesonide
Intervention Type
Drug
Intervention Name(s)
formoterol
Primary Outcome Measure Information:
Title
12 hour serial FEV1 measurements and withdrawals due to asthma exacerbation
Time Frame
FEV1: before start of tretment and at 2 and 12 weeks after start of treatment. Withdrawals: throughout the treatment period
Secondary Outcome Measure Information:
Title
Lung function, asthma symptoms, use of rescue medication, adverse events and other safety assessments
Time Frame
Throughout the treatment period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
At least 12 years of age
Diagnosis of asthma
Baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol
Exclusion Criteria:
Has required treatment with non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers
Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Catherine Bonuccelli
Organizational Affiliation
AstraZeneca
Official's Role
Study Director
12. IPD Sharing Statement
Citations:
PubMed Identifier
27039236
Citation
Tashkin DP, Moore GE, Trudo F, DePietro M, Chipps BE. Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma. J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):705-12. doi: 10.1016/j.jaip.2016.02.014. Epub 2016 Mar 30.
Results Reference
derived
PubMed Identifier
24524222
Citation
Tashkin DP, Chipps BE, Trudo F, Zangrilli JG. Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. J Asthma. 2014 Aug;51(6):603-9. doi: 10.3109/02770903.2014.895012. Epub 2014 Mar 19.
Results Reference
derived
PubMed Identifier
22329608
Citation
Murphy KR, Uryniak T, Martin UJ, Zangrilli J. The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma. Drugs R D. 2012 Mar 1;12(1):9-14. doi: 10.2165/11630600-000000000-00000. Erratum In: Drugs R D. 2012 Mar 1;12(1):15.
Results Reference
derived
Learn more about this trial
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
We'll reach out to this number within 24 hrs